UY34959A - DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR - Google Patents

DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR

Info

Publication number
UY34959A
UY34959A UY0001034959A UY34959A UY34959A UY 34959 A UY34959 A UY 34959A UY 0001034959 A UY0001034959 A UY 0001034959A UY 34959 A UY34959 A UY 34959A UY 34959 A UY34959 A UY 34959A
Authority
UY
Uruguay
Prior art keywords
inhibitors
compounds
dihydropiridone
present
xia factor
Prior art date
Application number
UY0001034959A
Other languages
Spanish (es)
Inventor
Yang Wu
James R Corte
Paul J Gilligan
Donald J P Pinto
William R Ewing
Wang Yufeng
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY34959A publication Critical patent/UY34959A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención provee compuestos de la Fórmula (VIII), o estereoisómeros, tautómeros o sales de aquellos aceptables desde el punto de vista farmacéutico, en donde todas las variables son como se definen en la presente. Estos compuestos son inhibidores selectivos del factor XIa o inhibidores duales de FXIa y calicreína plasmática. La presente invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos y a métodos para tratar trastornos tromboembólicos y/o inflamatorios mediante su uso.The present invention provides compounds of the Formula (VIII), or stereoisomers, tautomers or salts of those pharmaceutically acceptable, wherein all the variables are as defined herein. These compounds are selective inhibitors of factor XIa or dual inhibitors of FXIa and plasma kallikrein. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods for treating thromboembolic and / or inflammatory disorders by use.

UY0001034959A 2012-08-03 2013-08-02 DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR UY34959A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261679197P 2012-08-03 2012-08-03
US201361786992P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY34959A true UY34959A (en) 2014-01-31

Family

ID=48949289

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034959A UY34959A (en) 2012-08-03 2013-08-02 DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR

Country Status (26)

Country Link
US (2) US9376444B2 (en)
EP (1) EP2882734B1 (en)
JP (1) JP6082462B2 (en)
KR (1) KR20150038369A (en)
AR (1) AR093759A1 (en)
AU (1) AU2013296258A1 (en)
BR (1) BR112015002293A2 (en)
CA (1) CA2880898A1 (en)
CY (1) CY1118450T1 (en)
DK (1) DK2882734T3 (en)
EA (1) EA025392B1 (en)
ES (1) ES2605824T3 (en)
HR (1) HRP20161378T1 (en)
HU (1) HUE031582T2 (en)
IL (1) IL237012A0 (en)
LT (1) LT2882734T (en)
MX (1) MX361370B (en)
PL (1) PL2882734T3 (en)
PT (1) PT2882734T (en)
RS (1) RS55581B1 (en)
SG (1) SG11201500270RA (en)
SI (1) SI2882734T1 (en)
SM (1) SMT201700003B (en)
TW (1) TW201410666A (en)
UY (1) UY34959A (en)
WO (1) WO2014022766A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201319068A (en) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 Cyclic P1 linkers as factor XIa inhibitors
TW201311689A (en) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 Novel macrocycles as factor XIa inhibitors
ES2699226T3 (en) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as inhibitors of factor XIa
ES2579832T3 (en) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
CA2851810C (en) 2011-10-14 2020-01-07 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
BR112015007937A2 (en) 2012-10-12 2017-07-04 Bristol Myers Squibb Co crystalline forms of a factor xia inhibitor
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
TWI633089B (en) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 Substituted oxopyridine derivatives
NO2760821T3 (en) 2014-01-31 2018-03-10
RS57659B1 (en) * 2014-01-31 2018-11-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
EP3104701B1 (en) 2014-02-11 2019-01-30 Merck Sharp & Dohme Corp. Factor xia inhibitors
US9944643B2 (en) * 2014-02-11 2018-04-17 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US10081623B2 (en) 2014-09-04 2018-09-25 Bristol-Myers Squibb Company Diamide macrocycles that are FXIa inhibitors
NO2721243T3 (en) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors
WO2017019821A1 (en) 2015-07-29 2017-02-02 Bristol-Myers Squibb Company Factor xia new macrocycle bearing a non-aromatic p2' group
JP6629958B2 (en) 2015-07-29 2020-01-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Macrocyclic factor XIa inhibitors bearing alkyl or cycloalkyl P2 'groups
MA43128A (en) * 2015-10-29 2018-09-05 Merck Sharp & Dohme FACTOR XIA INHIBITORS
EP3371162B1 (en) * 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
KR20180117156A (en) * 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 Diamide macrocycle with factor XIa inhibitory activity
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors
AU2020257911B2 (en) 2019-04-16 2023-01-05 China Resources Biopharmaceutical Company Limited Macrocyclic derivatives acting as XIa factor inhibitor
WO2021013209A1 (en) 2019-07-23 2021-01-28 南京明德新药研发有限公司 Macrocyclic derivatives as factor xia inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
AR035216A1 (en) 2000-12-01 2004-05-05 Astrazeneca Ab MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS
PL204263B1 (en) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CN101137412B (en) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 Substituted biaryl compounds as factor xia inhibitors
WO2006089005A2 (en) 2005-02-17 2006-08-24 Bristol-Myers Squibb Company Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
WO2007070818A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
KR20080087817A (en) 2005-12-14 2008-10-01 브리스톨-마이어스 스큅 컴퍼니 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
US8466295B2 (en) 2005-12-14 2013-06-18 Bristol-Myers Squibb Company Thiophene derivatives as factor XIa inhibitors
JP5342450B2 (en) 2006-12-15 2013-11-13 ブリストル−マイヤーズ スクイブ カンパニー Arylpropionamide, arylacrylamide, arylpropinamide, or arylmethylurea analogs as factor XIa inhibitors
PE20081775A1 (en) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA
MX2009012847A (en) 2007-06-13 2009-12-08 Bristol Myers Squibb Co Dipeptide analogs as coagulation factor inhibitors.
WO2009114677A1 (en) 2008-03-13 2009-09-17 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
EP3786165A1 (en) 2010-02-11 2021-03-03 Bristol-Myers Squibb Company Synthetic intermediates for producing macrocycles as factor xia inhibitors
TW201311689A (en) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 Novel macrocycles as factor XIa inhibitors
TW201319068A (en) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 Cyclic P1 linkers as factor XIa inhibitors
CA2851810C (en) 2011-10-14 2020-01-07 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2579832T3 (en) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
ES2699226T3 (en) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as inhibitors of factor XIa
CA2859604C (en) 2011-12-21 2019-12-17 Ono Pharmaceutical Co., Ltd. Compounds
JP2015083542A (en) 2012-02-08 2015-04-30 大日本住友製薬株式会社 Three substituted proline derivative
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds

Also Published As

Publication number Publication date
IL237012A0 (en) 2015-03-31
CA2880898A1 (en) 2014-02-06
PL2882734T3 (en) 2017-05-31
US9376444B2 (en) 2016-06-28
ES2605824T3 (en) 2017-03-16
WO2014022766A1 (en) 2014-02-06
SG11201500270RA (en) 2015-03-30
CY1118450T1 (en) 2017-06-28
JP2015524443A (en) 2015-08-24
AR093759A1 (en) 2015-06-24
MX2015000919A (en) 2015-09-21
BR112015002293A2 (en) 2017-07-04
US20150166550A1 (en) 2015-06-18
AU2013296258A1 (en) 2015-03-19
TW201410666A (en) 2014-03-16
SI2882734T1 (en) 2017-01-31
PT2882734T (en) 2016-12-09
HRP20161378T1 (en) 2016-12-02
RS55581B1 (en) 2017-06-30
JP6082462B2 (en) 2017-02-15
CN104520289A (en) 2015-04-15
EP2882734B1 (en) 2016-10-12
HUE031582T2 (en) 2017-07-28
EP2882734A1 (en) 2015-06-17
DK2882734T3 (en) 2017-01-30
EA201590284A1 (en) 2015-05-29
SMT201700003B (en) 2017-03-08
LT2882734T (en) 2016-12-12
MX361370B (en) 2018-12-05
US20140038969A1 (en) 2014-02-06
EA025392B1 (en) 2016-12-30
KR20150038369A (en) 2015-04-08

Similar Documents

Publication Publication Date Title
UY34959A (en) DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR
UY34960A (en) DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR
UY35971A (en) MACROCICLOS WITH GROUPS P2? AROMATICS AS INHIBITORS OF THE XIA FACTOR
UY36244A (en) DERIVATIVES OF PYRIMIDINONE AS INHIBITORS OF THE XIA FACTOR AND / OR THE PLASMA CALICREINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY35972A (en) FXIA MACROCYCLIC INHIBITORS THAT HAVE HETEROCYCLIC GROUPS
CO2017001152A2 (en) Spirocycloheptanes as inhibitors of rho (rock) kinase
UY36170A (en) DIHYDROISOQUINOLINONA SUBSTITUTED COMPOUNDS
CO6551666A2 (en) MACROCICLES AS INHIBITORS OF THE COAGULATION FACTOR (FXIA)
DOP2015000157A (en) FUSIONED LACTAMAS OF ARILO AND HETEROARILO
DOP2014000152A (en) BROMODOMINIUM INHIBITORS
ECSP15045801A (en) 6-(5-HYDROXY-1H-PYRAZOLE-1-IL)NICOTINAMIDE PHD INHIBITORS
JO3425B1 (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
MX2015013042A (en) Organic compounds.
CU20170085A7 (en) IMIDAZOLIDINDIONA DERIVATIVES FOR THE TREATMENT OF OSTEOARTRITIS
CU24263B1 (en) DERIVATIVES OF IMIDAZOPIRIDAZINAS INHIBITORS OF QUINASA AKT, USEFUL FOR THE TREATMENT OF CANCER
UY34955A (en) 4-METHYL-2,3,5,9,9B-PENTAAZA-CICLOPENTA [A] NAFTALENOS
UY33557A (en) OXADIAZOL INHIBITORS OF LEUCOTRENE PRODUCTION
CR20160600A (en) QUINOLIZIONE DERIVATIVES AS PI3K INHIBITORS
SV2016005310A (en) DERIVATIVES OF DIHETEROCICLO LINKED TO CYCLALKYL